Skip to main content

Seegene

Global (Global)
Brazil (Brasil)
Germany (Deutschland)
Italy (Italia)
Korea (대한민국)
Mexico (México)
Middle East (الأوسط الشرق)
United States (United States)

Search this site

Discover related topics

Seegene Proposes Comprehensive Reproductive Tract Infection Testing Approach through the Global Million Clinical Study Seegene USA Receives FDA Emergency Use Authorization for Multiplex PCR Assay, Advancing Differential Diagnosis of HSV-1&2, VZV, and Monkeypox Virus for Ulcerative Skin Lesions Seegene: “Virus-Only Testing May Miss Pneumonia-associated Bacterial Respiratory Pathogens” Calls for a Shift to Comprehensive Syndromic PCR Testing Seegene Launches Industry’s First Global Million Clinical Study to Shape New Disease-Specific Testing Standards Seegene Launches Allplex™ MDRO Assay Under IVDR: Expanding AMR Testing Portfolio in Europe Seegene Introduces STAgora at ESCMID Global 2026, Highlighting Real-Time Data with Automated PCR Workflows Seegene Establishes French Subsidiary to Expand European Footprint Seegene and Springer Nature Open Applications for 2025-2026 Nature Awards MDx Impact Grants Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advancing the Next Stage of Diagnostics Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics Seegene’s CURECA™ Emerges as a Potential Game Changer in End-to-End PCR Automation Seegene Announces Development of CURECA™, a Next-Generation Fully Automated PCR Solution Featuring Customizable Pre-treatment Automation Seegene Unveils HPV Genotyping Solution at EUROGIN 2025 Seegene Holds Partner Executive Roundtable with Microsoft, and Springer Nature, Accelerating its Technology-Sharing Initiative Seegene and Werfen Finalize Partnership Agreement on Technology-Sharing Initiative Seegene Expands mpox RUO Product Lineups with Enhanced Detection Assays for Clade 1 Seegene and Springer Nature Launch ‘Nature Awards MDx Impact Grants’ to Innovate Syndromic PCR Diagnostic Assays Seegene Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration Seegene Showcased Its Multiplex Technology at ADLM 2024 Seegene Showcases HPV Diagnostic Kits and PCR Technology at AOGIN 2024 Seegene and Springer Nature Announce Strategic Alliance Seegene and Springer Nature Announce Awardees for the Open Innovation Program Seegene and UK Health Security Agency convene a summit to collectively realize “a World Free from All Diseases”Seegene Announces Collaboration with Microsoft to Realize ‘a World Free from All Diseases’Seegene obtains ISO45001 certification Seegene Earns Improved ESG Rating from the Korea Institute of Corporate Governance and Sustainability Seegene Reinforces Commitment to Strong ESG Management with 100% Recyclable, Styrofoam-Free Shipping Boxes Seegene Unveils ‘Open Innovation Program Powered by Seegene’ in Partnership with Springer Nature Seegene unveils solutions to popularize molecular diagnostics at 2023 AACC Springer Nature to Join Seegene’s OneSystem™ Business as Strategic Partner Seegene and Werfen Partner to Collaborate on OneSystem™ Business to Develop Syndromic qPCR Assays Seegene Obtains IVDR Certification for 30 Diagnostic Assays IVI and Seegene's Partnership to Tackle HPV in Developing Countries through Advanced Diagnostic Technology Seegene declares to share Syndromic PCR technologies to prevent future pandemics Seegene Wins Tender for Diagnostic Reagents Worth 45 Million Euros in Italy Seegene unveils strategies for global expansion at 2022 AACC Seegene to pave way for PCR testing at local clinics with EU-approved multiplex test and fully automated PCR solution Seegene develops PCR test to detect monkeypox virus Seegene unveils ‘$12 PCR testing’ initiative to help end COVID-19 pandemic Seegene reports first quarter 2022 financial results Seegene unveils world’s first commercialized ‘3 Ct’ PCR assay Seegene’s Allplex™ RV Master Assay receives Australian TGA approval, European CE mark Seegene appoints Dr. Glen Hansen as Head of Medical Affairs of U.S. subsidiary Seegene appoints Richard Creager as CEO of U.S. subsidiary to bolster U.S. business Seegene unveils new assay optimized for on-site testing in ‘living with Covid-19’ era Seegene Signs Supply Deal to Deliver 4 million COVID-19 Tests to Brazil Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing Seegene Continues to Support Israel’s Effort to Manage the Omicron Variant With Timely Delivery of Five Million Tests Seegene’s Allplex™ SARS CoV-2 FluA/FluB/RSV Assay approved under Health Canada’s Interim Order Seegene Unveils Blueprint for the Future of Molecular Diagnostics, Including Open Development Platform at the 40th Annual J.P. Morgan Healthcare Conference Seegene Airlifts 1.7 million COVID-19 Tests to Israel Battling the Omicron Variant by a charter plane PR Newswire Seegene Rapidly Introduces New PCR Test that Identifies the Omicron Variant, its Stealth Version, and all VOCs in a single tube Seegene’s High Multiplex PCR Assay Capable of Detecting New Omicron Variant Seegene Announces Q3 2021 Earnings, Continuing COVID-Era Momentum Seegene Opens New Subsidiary in Bogotá, Colombia, to Advance Regional COVID-19 Testing Launch of Seegene’s STARlet-AIOS: All-in-One System Fulfills Critical Need for Fully Automated, High-Throughput Real-Time PCR Testing Seegene Unveils Fully Automated Molecular Testing System at the 2021 AACC Seegene Receives CE-IVD Mark for Use of Combo Swab, a Self-Collection Device with Four COVID-19 Diagnostic Tests Seegene Q2 2021 Earnings Show 11 Percent Revenue Growth, YoY Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus Seegene announces partnership with Bio-Rad to develop diagnostic testing products for the U.S. Market PR Newswire Seegene unveils "MOBILE STATION," for on-site routine testing at public-use facilities and communities Seegene introduces an exclusive diagnostic system for diagnosing COVID-19 variants at ECCMID Seegene reports solid results in the first quarter of 2021 with KRW 351.8 billion Seegene’s Germany subsidiary supports the back-to-school initiative with its COVID-19 tests Seegene to supply COVID-19 diagnostic tests worth 16 mil. GBP to Scotland, triple the sales volume seen last year Seegene begins exporting its latest COVID-19 variant tests around the world to help contain spread of pandemic Seegene supports Mexico’s ‘back to school’ campaign with COVID-19 tests and face masks Seegene’s Latest COVID-19 Test Can Simultaneously Target 4 Genes of SARS-CoV-2 and Recognize Multiple Virus Variants Seegene Announces Submission to U.S. FDA for Emergency Use Authorization of Its Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay Seegene’s saliva test for COVID-19 is just as effective as NPS test Seegene develops world first COVID-19 variant test capable of identifying origins of virus variants Seegene to advance business in Latin America in the New Year Seegene’s COVID-19 test with saliva sample collection feature now available in Europe Seegene donates 20,000 COVID-19 tests to Ecuador Seegene’s aggregated sales surpass KRW 1 tril. this year; plans on expanding annual production capacity to KRW 5 tril. in 2021 Seegene’s COVID-19/FluA,B/RSV test with extraction-free feature now available in Europe Global biotech firm Seegene posts a record high in Q3 sales Seegene Exports 10 million Corona Tests to Brazil Seegene’s Allplex™ 2019-nCoV Assay receives FDA Emergency Use Authorization Seegene exported 10 Million COVID-19 Diagnostic Tests to Over 60 countries Seegene Receives Health Canada Approval for its COVID-19 Assay Seegene launches KFDA Approved COVID-19 Assay Seegene Highlights Clinical Automated Nucleic Acid Extraction System at ASM Microbe 2019 Seegene Establishes Brazilian Subsidiary Seegene Brazil Diagnostics LTDA to target IVD market in Latin America Seegene launches a new anti-microbial drug resistance test kit, replacing the conventional culture method Seegene Unveils New Real-time PCR Analysis Technology, Drastically Increasing Its Multiplexing Capacity Seegene Unveils Combination Test at ECCMID 2018 Seegene develops world’s first multiplex MDx assays with its AI system Seegene inks MOU with global automated instrumentation leader Hamilton Company Seegene accelerates ‘Project 100’ by securing 30 co-development partners Unique concept of MDx, Seegene Random Access System, announced at AACC 2017 Seegene Signed MOU with a Mexico Government Agriculture Agency for Collaborative Development of Non-human MDx Assay Seegene enters the U.S. diagnostic market in collaboration with Thermo Fisher Scientific Seegene Unlocks the Door to the Next Level of the Real-time PCR Business Seegene Develops New Normalization Software Technology for Molecular Diagnosis Seegene and Institut Catala d Seegene and Hologic Form Worldwide Collaboration to Develop High Multiplex Molecular Diagnostic Assays Seegene to Introduce Automated Development of in silico-based Multiplex Real-time PCR Assays Seegene to Introduce Novel Real-Time PCR Technology at ASM Microbe 2016 Seegene Technologies to Unleash Customized Multiplex PCR Solutions and Support for U.S. Market Seegene Establishes Joint Venture in Mexico Seegene and BD Form Worldwide Collaboration to Develop Multiplex Molecular Diagnostic Assays Seegene and QIAGEN Enter into a Collaboration to Develop Multiplex Molecular Diagnostic Assay Seegene Establishes U.S. Subsidiary. Seegene Technologies Inc. to Drive Growth in the U.S. and Global Molecular Diagnostics Market Seegene Receives Health Canada Approval for its new Allplex™ Respiratory Molecular Test Seegene Receives FDA Clearance for its Herpes Simplex Virus Molecular Test Seegene to Present at the 33rd annual J.P. Morgan Healthcare Conference Seegene to Unveil at AACC 2014 the Innovative Real-Time PCR Technology That Doubles the Channel Availability of Any Real-Time PCR Instrument Seegene to Present at the 32nd Annual J.P. Morgan Healthcare Conference Seegene and Eidia Collaborate to Bring New Multiplex Molecular Diagnostic Tests to Japan Seegene to feature extended mutation detection technology for companion diagnostics at AACC 2013 Seegene Names John G. Hurrell as Senior Executive Vice President Seegene to Unveil Groundbreaking Technology for Highly Multiplexed Quantitative Real-Time Molecular Assays at AACC 2012 Seegene to introduce real-time multiple mutation detection technology for drug resistant mutations in M. tuberculosis at AACC 2012 Seegene Introduces the First Real Time Multiplex Quantification Test for Human Papilloma Virus (HPV)Seegene Introduces the Industry's First Real-Time Multiplex Quantification Assay for Respiratory Diseases Seegene Develops Highly Multiplexed Quantitative Real-Time PCR Chemistry, HPV Genotyping Assay Seegene develops industry’s first real-time "multiplex quantification" molecular diagnostic testing technology Seegene and DuPont Nutrition & Health Agree to Develop Highly Multiplexed Molecular Assays for Food Safety Testing Seegene Strengthens Position in Multiplex PCR with Award of United States Patent for Dual Priming Oligonucleotide (DPO™) Technology Seegene Introduces Anyplex™ II STI-7 Detection Assay Seegene Introduces Anyplex™ plus MTB/NTM/DR-TB Real-time Test, a ...Seegene Announces a New Concept of Real-time Multiplex Diagnostic Technology Akonni and Seegene Combine Technologies to Develop Respiratory Pathogen MDx Platform

OUR COMPANY
PRODUCT
MEDIA
- Media Center
INVESTORS
- Earnings Release
- Financial Statement
INSIGHT
- Publications
- Events
SUSTAINABILITY

Privacy Policy
Cookie Policy
Terms of Use
Accessibility

©2026 Seegene Inc. All rights reserved.